YHC2157

YHC2157 is a preclinical biologic drug candidate being developed by Yuhan Corporation for the treatment of asthma and allergic diseases. It is categorized as an antiallergic and antiasthmatic agent that functions by inhibiting inflammation and acting as an immunosuppressant. As an early-stage asset in Yuhan's immune and inflammation pipeline, it is currently undergoing preclinical research to evaluate its potential in managing respiratory and allergic conditions. The drug is part of Yuhan's broader strategy to expand its presence in the allergy treatment market, following other assets like the IgE inhibitor YH35324.